Cargando…
Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients
BACKGROUND: By depleting circulating B lymphocytes, rituximab time-dependently suppresses coronavirus disease 2019 (COVID-19) vaccines’ humoral immunogenicity for a prolonged period. The optimal time to vaccinate rituximab-exposed immune-mediated dermatologic disease (IMDD) patients is currently unc...
Autores principales: | Seree-aphinan, Chutima, Ratanapokasatit, Yanisa, Suchonwanit, Poonkiat, Rattanakaemakorn, Ploysyne, O-Charoen, Pichaya, Pisitkun, Prapaporn, Suangtamai, Thanitta, Setthaudom, Chavachol, Chirasuthat, Sonphet, Chanprapaph, Kumutnart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050596/ https://www.ncbi.nlm.nih.gov/pubmed/37006291 http://dx.doi.org/10.3389/fimmu.2023.1138765 |
Ejemplares similares
-
Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
por: Seree-aphinan, Chutima, et al.
Publicado: (2021) -
Refractory Bullous Systemic Lupus Erythematosus Successfully Treated with Rituximab: A Case Report and Literature Review
por: Ratanapokasatit, Yanisa, et al.
Publicado: (2023) -
Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy
por: Rattanakaemakorn, Ploysyne, et al.
Publicado: (2021) -
Pityriasis Lichenoides Et Varioliformis Acuta and Lymphomatoid Papulosis Type F: A Case Report of Two Entities in One Patient
por: Pomsoong, Cherrin, et al.
Publicado: (2022) -
Serum sickness-like reaction following an administration of the first dose of inactivated COVID19 vaccine
por: Chaijaras, Sasipim, et al.
Publicado: (2021)